The following main resolutions were resolved upon at the AGM:

Adoption of income statement and balance sheet for the company and the group

The AGM resolved to adopt the presented income statement and balance sheet for the company and the group.

Allocation of result

The AGM resolved, in accordance with the Board of Directors' proposal, that available founds is balanced in the new account and thus no dividends are paid for the financial year 2023.

Discharge from liability

The AGM resolved on the discharge from liability for board members and the CEO for the financial year 2023.

Determination of number of board members, deputy board members and the number of auditors and determination of fees to the board and auditors and auditor

The AGM resolved, in accordance with the Nomination Committee's proposal, that, for the period until the next AGM is held, the Board of Directors is to be comprised of five members without deputies. Fees to the Board of Directors are to be paid with ten price base amounts to the chairman and with five price base amounts to each of the other board members who are not employed by the company. Furthermore, the AGM resolved, in accordance with the Nomination Committee's proposal, that for the period until the end of the next AGM, one auditor shall be appointed and that fees to the auditors shall be paid according to invoices approved by the company.

Election of directors, deputies, and auditors

The AGM resolved to re-elect the board members Anders Svensson, Joakim Söderström, and Jeppe Øvlesen and that Gunnar Olsson and Sten R. Sörensen be elected as new board members. Joakim Söderström was re-elected as chairman of the Board of Directors. The AGM resolved to re-elect Frejs Revisorer AB as the company's auditor. Frejs Revisorer AB has informed the company that Mikael Glimstedt will continue as principal auditor.

Principles for the Nomination Committee

The AGM resolved to adopt the Nomination Committee's proposed principles for the Nomination Committee.

Resolution on adoption of new Articles of Association

The AGM resolved to adopt the Board of Directors proposal to adopt new Articles of Association.

Resolution on a directed issue of warrants to executives

The AGM resolved in accordance with the Board of Directors proposal to issue warrants to executives of the company.

Resolution on a directed issue of warrants to a key employee

The AGM resolved in accordance with a shareholder group's proposal to issue warrants to a key employee of the company.

Resolution on authorization for the Board of Directors to issue shares and/or warrants and/or convertibles

The AGM resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors to resolve, on one or several occasions, on issue of shares and/or warrants and/or convertibles during the time until the next AGM.

The complete proposals of the Nomination Committee, the Board of Directors, and the shareholder group are available on the company's website, www.cerenoscientific.com.

For further information, please contact:

Henrik Westdahl, Director IR & Communications
E-mail: henrik.westdahl@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA's Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator - regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B).More information on www.cerenoscientific.com.